109 related articles for article (PubMed ID: 9891516)
1. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428.
Alonso DF; Tejera AM; Farias EF; Bal de Kier Joffe E; Gomez DE
Anticancer Res; 1998; 18(6A):4499-504. PubMed ID: 9891516
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma.
Todaro LB; Ladeda V; Bal de Kier Joffé E; Farías EF
Oncol Rep; 2003; 10(3):725-32. PubMed ID: 12684650
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
4. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.
Alonso DF; Farías EF; Ladeda V; Davel L; Puricelli L; Bal de Kier Joffé E
Breast Cancer Res Treat; 1996; 40(3):209-23. PubMed ID: 8883963
[TBL] [Abstract][Full Text] [Related]
5. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Xing RH; Mazar A; Henkin J; Rabbani SA
Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
[TBL] [Abstract][Full Text] [Related]
6. Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells.
Alonso DF; De Lorenzo MS; Tejera AM; Gomez DE
Oncol Rep; 1998; 5(1):209-12. PubMed ID: 9458324
[TBL] [Abstract][Full Text] [Related]
7. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
8. Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428.
Evans DM; Sloan-Stakleff K
Am Surg; 2000 May; 66(5):460-4. PubMed ID: 10824746
[TBL] [Abstract][Full Text] [Related]
9. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
10. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
11. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
12. Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma.
Alonso DF; Farías EF; Urtreger A; Ladeda V; Vidal MC; Bal De Kier Joffé E
J Surg Oncol; 1996 Aug; 62(4):288-97. PubMed ID: 8691844
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
14. Myricetin suppresses invasion and migration of human lung adenocarcinoma A549 cells: possible mediation by blocking the ERK signaling pathway.
Shih YW; Wu PF; Lee YC; Shi MD; Chiang TA
J Agric Food Chem; 2009 May; 57(9):3490-9. PubMed ID: 19326946
[TBL] [Abstract][Full Text] [Related]
15. Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer.
Evans DM; Sloan-Stakleff KD
Invasion Metastasis; 1998-1999; 18(5-6):252-60. PubMed ID: 10729770
[TBL] [Abstract][Full Text] [Related]
16. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
17. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Guo Y; Mazar AP; Lebrun JJ; Rabbani SA
Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
Park MJ; Lee JY; Kwak HJ; Park CM; Lee HC; Woo SH; Jin HO; Han CJ; An S; Lee SH; Chung HY; Park IC; Hong SI; Rhee CH
J Cell Biochem; 2005 Aug; 95(5):955-69. PubMed ID: 15962302
[TBL] [Abstract][Full Text] [Related]
19. Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer.
Farina HG; Pomies M; Alonso DF; Gomez DE
Oncol Rep; 2006 Oct; 16(4):885-91. PubMed ID: 16969510
[TBL] [Abstract][Full Text] [Related]
20. Novel laminin 5 gamma 2-chain fragments potentiating the limbal epithelial cell outgrowth on amniotic membrane.
Cheng CY; Sun CC; Yu WH; Hsieh HL; Ma DH; Pang JH; Yang CM
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4631-9. PubMed ID: 19420329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
